Wyoming Vaccine Advisory Board (VAB) Meeting Minutes
Thursday, November 9, 2011
8:30 a.m. - 9:30 a.m.

Location: CenturyLink Building, 6101 Yellowstone Road, Suite 420, Room 417, Cheyenne, Wyoming
Dial-in Number: **1-877-278-8686,** Participant PIN: **309491**

Present:

Wendy E. Braund, M.D., M.P.H., M.S.Ed, State Health Officer and Senior Administrator
Jan Bloom, Immunization Program Chief
Lisa Wordeman, Vaccine Program Specialist
Diana Martin, R.N., Clinical Quality and Compliance Specialist
Valerie Koch, R.N., Clinical Quality and Compliance Specialist
Jackie Nelson, M.D., American Academy of Pediatrics
Jodye Wilmes, R.N., State Program Consultant
Chris Bartholomew, R.N., Wyoming School Nurses Association
Barry Wohl, M.D., General Pediatrician, Northeast Wyoming Pediatrics Associates
Michael Tracy, M.D., Wyoming Chapter President, American Academy of Pediatrics
Robert Prentice, M.D., General Pediatrician, Cheyenne Children's Clinic
LaChel May, Vaccine Program, Provider Relations Administrative Assistant

---

Meeting called to order by Dr. Wendy Braund at 8:30 a.m.

Welcome and Introductions- Jan Bloom, Immunization Program Manager, introduced Dr. Wendy Braund, Wyoming State Health Officer and Public Health Division Senior Administrator, to the Vaccine Advisory Board Members.

Vaccine Fiscal Report- Jan Bloom reported on where the program stands in the current biennium budget. As of July 1, 2011, the Immunization Program transitioned to a Universal Select supply policy due to a budget short fall.

Emerging Vaccine Issues- Diana Martin, Clinical Quality & Compliance Specialist, reported on the most recent Advisory Committee for Immunization Practices (ACIP) meetings, which were held in June and October of 2011.

The ACIP reported the following updates, relevant to the Wyoming Vaccinates Important People (WyVIP) program:

- **Influenza & the Egg Allergy Patient:** The committee recommends that an allergy to eggs be changed from a contraindication to a precaution for flu vaccine for the Trivalent Inactivated Vaccine (TIV). Live, attenuated influenza vaccine or LAIV should not be used in patients who report an egg allergy.
- **Meningococcal: T**he ACIP voted to recommend a two-dose series of quadrivalent meningococcal conjugate vaccine (MCV4) starting at age 9 months for children with specific complement deficiencies and for those traveling to, or living in, areas where meningococcal disease is endemic. The MCV4 recommendation for children with asplenia, however, remains at 2 years.
- **Measles:** A total of 156 cases of measles have been reported in the US in 2011, of which, 85% involved unvaccinated patients or patients with an unknown vaccination status.
- **Vaccines and febrile seizures:** A subgroup of the General Recommendations Committee was created to look at the incidence of febrile seizures with vaccines. Updated data show that confirmed febrile seizures with TIV and PCV occur in about 1 in 2,375 vaccines. The workgroup concluded that the risk of disease was much greater than the risk of febrile seizures. No change was made to the ACIP recommendation.
- **HPV4** (Gardasil) was approved for males 11-12 years old, as a 3-dose series, which can be started as soon as 9 years of age.
- **Schedule Format Changes:** There will be some formatting changes to the schedules to make it more readable and to include updated information.

Vaccine Inventory Report- Lisa Wordeman, Vaccine Program Specialist, reported on the current status of influenza vaccine.

Discussion- Jan Bloom relayed further information regarding the transition to a Universal Select supply policy, citing factors that led to the decision.

Next VAB meeting- The next meeting will be held on Wednesday, March 21, 2012, at 8:30 a.m. The board will meet in the CenturyLink Building in Cheyenne, located at 6101 Yellowstone Road, Suite 420, Room 417.

Meeting adjourned by Dr. Braund at 9:35 a.m.

Respectfully submitted by:
LaChel May, Provider Relations Administrative Assistant, Recorder